Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MERTK drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MERTK ECD-Fc Fusion Protein / Mutant Protein; HEK293 expressed, >95% purity, endotoxin <1EU/ug, Sequence Verified. | View MERTK Products |
| Gene Delivery | MERTK Promise-ORF / Lentivirus; Full-length ORF for stable cell lines. | View MERTK Products |
| Benchmark Ab | Anti-MERTK Recombinant Antibody (Neutralizing Clone); Positive control for binding and neutralization. | View MERTK Products |
| Validator | MERTK siRNA Set; For knockdown verification and specificity controls. | View MERTK Products |
| Related Target | AXL (TAM family, compensatory signaling) | View AXL Products |
| Related Target | TYRO3 (TAM family, heterodimerization) | View TYRO3 Products |
| Related Target | GAS6 (Primary endogenous ligand) | View GAS6 Products |
| Related Target | TIM-3 / HAVCR2 (Phosphatidylserine receptor for combination therapy) | View HAVCR2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| TAM Family Cross-reactivity (AXL/TYRO3) | Homolog panel (AXL, TYRO3, MERTK) strictly verified by mass spec for rigorous counter-screening. |
| ADC Internalization Efficiency | High-purity MERTK ECD-Fc (>95%) with native glycosylation pattern for accurate binding and internalization assays. |
| Cross-species Translation (Cyno/Mouse) | Human/Mouse/Cynomolgus MERTK ECD available, >95% purity, endotoxin <1EU/ug. |
| Lack of Reliable Controls | Sequence Verified Benchmark Antibody (neutralizing clone) included. |
| Cell-Based Assay False Positives | Validated MERTK siRNA set included for target-specificity confirmation. |
| Ligand Blocking & Binding | High-purity GAS6 protein for competitive binding studies. |
Live MERTK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MERTK therapeutics is intensifying, with major players shifting focus from pan-TAM inhibitors to highly selective modalities including small molecule inhibitors, monoclonal antibodies, Fc-fusion decoy receptors, ADCs, PROTACs, and bispecific constructs. MERTK, a key member of the TAM family (TYRO3, AXL, MERTK), plays a critical role in efferocytosis and macrophage checkpoint regulation, driving an immunosuppressive tumor microenvironment. Its extracellular region comprises two Ig-like C2-type domains and one fibronectin type-III domain (UniProt Q12866). Known non-synonymous mutations (e.g., rs35898499, rs13027171, rs56205303) have been cataloged, informing genetic analysis in drug development.
First-generation therapies such as bemcentinib (BerGenBio) and MRX-2843 (Mirati/BMS) are advancing through Phase II in AML and solid tumors. The next wave targets combinatorial strategies with PD-1/PD-L1 inhibitors (e.g., MERTK inhibitor + checkpoint blockade) to overcome innate immune resistance. Also emerging are antibody-drug conjugates (AstraZeneca, Eli Lilly) and protein degraders (PROTACs) designed to exploit MERTK's rapid internalization. The convergence of targeted therapy and immuno-oncology drives demand for reagents capable of validating both direct tumor killing and immune cell modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | BerGenBio, BMS, Mirati, ONO Pharma | AML, NSCLC, Melanoma, Solid Tumors | Kinase selectivity vs AXL/TYRO3 (need high-purity kinase domains and TAM panel) |
| Fc-Fusion Decoy | Aravive (batiraxcept) | Ovarian Cancer, RCC | Ligand blocking & stability (need HEK293-expressed ECD-Fc with native glycosylation) |
| Monoclonal Antibody | Genmab, Merus | Immunotherapy combinations | Ligand blocking assay (need ECD-Fc and GAS6 protein) |
| ADC / PROTAC / Bispecific | AstraZeneca, Eli Lilly, Emerging Biotechs | Solid Tumors, Refractory cancers | Internalization & cross-reactivity (need native antigen, Lentivirus, AXL/TYRO3 panel) |
| CAR-T / Cell Therapy | Academic / Preclinical | Hematologic Malignancies | Stable cell line construction (need MERTK Lentivirus) |
Key Functional Domains and Mutations
- Functional Domains (UniProt Q12866): Ig-like C2-type 1, Ig-like C2-type 2, Fibronectin type-III 1.
- Key Mutations (dbSNP): rs35898499, rs13027171, rs56205303 (non-synonymous variants with clinical relevance).